We could not find any results for:
Make sure your spelling is correct or try broadening your search.
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Top Brokers
Investor discussions surrounding Oxford Biomedica Plc (OXB) this week highlighted varying sentiments regarding the company's stock prospects and potential takeover interest. A participant expressed skepticism about a £7-9 bid being adequate, while another reported selling shares, suggesting fluctuating trading dynamics. Notably, discussions revealed apprehensions regarding OXB's defenses against opportunistic bids, with sentiments emerging that the company's current share price may suggest vulnerability. This concern was echoed when one investor observed, “I have to say that the impression I took from the AGM was that there was a feeling of potential vulnerability to an opportunistic bid.”
In terms of financial outlook, speculation on OXB’s revenues for the upcoming year indicated a prediction of approximately £180 million, pointing towards a year of record revenue. Quotes such as "the behavior of the company hasn't appeared to be helping their share price" encapsulated the frustration of investors amid perceived underperformance and challenges in the market context. Despite these concerns, discussions about the company's strategic position and future prospects remained active, with hopes for a more stable and significantly valued future. Several participants highlighted the potential impact of OXB's reintegration into indices like the FT250 as a catalyst for renewed investor interest. Overall, while some investors remain hopeful about OXB's future growth, underlying worries continue to cloud investor sentiment regarding its valuation and the competitive pharmaceutical market.
Show more
Oxford Biomedica Plc (LSE: OXB) has reported several key developments in recent weeks, highlighting its ongoing strategic initiatives and governance changes. Notably, as of December 2, 2024, the company's total issued share capital stands at 105,938,933 ordinary shares, which shareholders can use for determining notification obligations under the FCA's Disclosure Guidance. Additionally, new executive compensation arrangements were announced, including the grant of long-term incentive plan (LTIP) awards to key management, scaled back by 20% as part of best practice governance.
The company is also expanding its engagement in the biopharmaceutical community, with a forthcoming free webinar scheduled for December 9, 2024, focused on the use of advanced robotics in accelerating the development of viral vector products. This reflects OXB's commitment to innovation in cell and gene therapy manufacturing. Furthermore, the Board has undergone changes with the appointment of Colin Bond as a new Non-Executive Director, effective January 1, 2025, as part of planned succession efforts. These developments demonstrate OXB's proactive approach to governance and its focus on enhancing operational capabilities within the competitive biopharmaceutical landscape.
Show more
Looks to me like Liontrust simply wanted to go under the 5% boundary, but why that's significant for them I've no idea. |
I think a lot of these websites just want traffic - i.e. they don't care if you follow the latest computer generated tip or not - they just want people who follow popular shares to click to look at the latest tip so that the website owner gets a penny from each of the advertisers on the page. Enough traffic and it must be quite lucrative else they wouldn't be able to pay Google monthly protection money to always come up near the top in the company name searches. |
if Liontrust are distressed sellers then we need to wait until they have cleared out their sale orders - is this now the case? |
My guess would simply be the budget Dom. |
If they wanted it down,and back to where it was languishing a fortnight ago, what was the breakout through £4 for? |
I'm pretty confident that OXB have at least one "proper" RNS locked and loaded. |
Yes indeed but i think its very easy for companies to concentrate on the job in hand,especially when they're involved in an esoteric science like biotech.A lot of senior management don't give two figs for the stock exchange and don't have much confidence that some teenage scribbler will fully understand their business.They probably have a point.Ultimately,the proof of the pudding will be in the eating and the reality will out.Looking at the way the Oxford Biomedica share price has moved over the last three years,you could be forgiven for believing the stock exchange is a complete lottery.I have long felt that numerous smaller companies would be better off staying private.That said,i agree,if you are listed you should make every effort to communicate your corporate message effectively. |
Steeplejack. Isn't that an argument to support companies, especially smaller companies, to use their own publicity departments to promote the company? |
I agree Dom. |
You know me well Mr President Sir, but the issue is ANY attempt to promote the share value is absent other than relying on two occasions in the year, Interims and Results. Not good enough these days. |
takeiteasy, |
Dom, |
hxxps://www.closebro |
#9036 Nor have we released any market sensitive news. Perhaps there is no equivalent to 'RNS' in French? |
Only if there are enormous funds out there which are either techmark LSE index trackers or have fund rules which include techmark LSE index constituents as an option. |
Harry, we have never left the techmark LSE index - has that helped though? :) |
With the budget / budget management campaign (pre-budget leaks of much worse) now over, I think the 3 points listed below will determine whether the new year's eve party (2 months tonight) is M&S best ever sausage rolls or Tesco value. |
In their previous sales to meet fund redemptions there has often been a news release saying that they have sold the same tiny percentage of everything they hold. |
and sell their top performing share lols...active management in practice lols :) |
So more Liontrust redemptions then - maybe in anticipation of a worse budget? |
Might come to nothing and I'm sure some of you remember from the 10 days of interims countdown, but... GeoVax |
The budget could have been worse and in the years ahead probably will be :) |
Well, the Budget bounce back didn't last long, did it? |
Beinng European for a moment..... |
Type | Ordinary Share |
Share ISIN | GB00BDFBVT43 |
Sector | Medicinal Chems,botanicl Pds |
Bid Price | 425.00 |
Offer Price | 427.00 |
Open | 430.00 |
Shares Traded | 258,355 |
Last Trade | 16:35:13 |
Low - High | 411.50 - 430.50 |
Turnover | 89.54M |
Profit | -184.16M |
EPS - Basic | -1.7479 |
PE Ratio | -2.43 |
Market Cap | 453.05M |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions